Symptomatic Aortic Stenosis Clinical Trial
Official title:
A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
NCT number | NCT02536196 |
Other study ID # | REFLECT |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2016 |
Est. completion date | June 2019 |
Verified date | February 2021 |
Source | Keystone Heart |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Keystone Heart TriGuard™ HDH is an aortic embolism deflection device intended to reduce the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries during transcatheter heart valve implantation. The objective of the study is to assess the safety and efficacy of the TriGuard™ HDH embolic deflection device in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison with an active control group of patients undergoing unprotected TAVI. Subjects with indications for TAVI and who meet study eligibility criteria will be randomized 2:1 to one of two treatment arms: 1) Intervention: Embolic protection device (TriGuard™) with transcatheter aortic valve implantation or 2) Control: Unprotected transcatheter aortic valve implantation.
Status | Completed |
Enrollment | 478 |
Est. completion date | June 2019 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Subjects must meet ALL of the following criteria: General Inclusion Criteria 1. The patient is a male or non-pregnant female =18 years of age 2. The patient meets indications for transcatheter aortic valve implantation (TAVI) 3. The patient is willing to comply with protocol-specified follow-up evaluations 4. The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC). Potential Subjects will be excluded if ANY of the following criteria apply: General Exclusion Criteria 1. Patients undergoing transcatheter aortic valve implantation (TAVI) via the trans-axillary, trans-subclavian, or trans-aortic route 2. Patients undergoing transcatheter aortic valve implantation (TAVI) via the transapical approach due to friable or mobile atherosclerotic plaque in the aortic arch 3. Patients with a previously implanted prosthetic aortic valve (i.e., planned valve-in-valve transcatheter aortic valve implantation (TAVI)) 4. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 14 days prior to index procedure per site standard test 5. Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (according to definition) or AMI >72 hours preceding the index procedure, in whom Creatine Kinase (CK) and CK-MB have not returned to within normal limits at the time of procedure, or patients who are currently experiencing clinical symptoms consistent with new-onset AMI, such as nitrate-unresponsive prolonged chest pain 6. Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, patients who will refuse transfusion, or patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 months 7. Patients with known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation, or is associated with a life expectancy of less than one year 8. Patients with severe allergy or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated 9. Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months 10. Patients with renal failure (estimated Glomerular Filtration Rate [eGFR] <30 mL/min, calculated from serum creatinine by the Cockcroft-Gault formula) 11. Patients with hepatic failure (Child-Pugh class C) 12. Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin 13. Patients presenting with cardiogenic shock at the time of the index procedure 14. Patients with severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath vascular access 15. Patients in whom the aortic arch, innominate artery ostium, or proximal innominate artery is heavily calcified, severely atheromatous, or severely tortuous 16. Patients with an innominate artery ostium diameter <10 mm or >25 mm 17. Patients with a transverse aortic diameter >43 18. Patients with anatomic irregularities of the innominate artery that could prevent positioning of the TriGuard upper stabilizer and compromise stability of the device 19. Patients with any other condition that would prevent adherence to the TriGuard HDH Instructions for Use 20. Patients with contraindication to cerebral MRI 21. Patients who have a planned treatment with any other investigational device or procedure during the study period 22. Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVI procedure or within 10 days prior to the TAVI procedure. NOTE: Diagnostic cardiac catheterization is permitted within 10 day prior to the TAVI procedure |
Country | Name | City | State |
---|---|---|---|
Germany | University of Bonn | Bonn | |
Germany | Universitats-Herzzentrum Freiburg | Freiburg | |
Germany | Hamburg Univeristy Cardiovascular Center | Hamburg | |
Germany | Leipzig Heart Institute | Leipzig | |
Italy | San Donato Hospital | Milano | |
Italy | San Rafeele Hospital | Milano | |
Netherlands | UMC Utrecht | Utrecht | |
United States | Piedmont Hospital | Atlanta | Georgia |
United States | University of Virginia | Charlottesville | Virginia |
United States | Morton Plant Hospital | Clearwater | Florida |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Baylor Heart and Vascular HospitalBaylor Heart and Vascular | Dallas | Texas |
United States | Northwestern University | Evanston | Illinois |
United States | Pinnacle Health | Harrisburg | Pennsylvania |
United States | Delray Medical Center | Hialeah | Florida |
United States | Cardiovascular Institute of the South | Houma | Louisiana |
United States | Houston Methodist Hospital | Houston | Texas |
United States | University of Texas | Houston | Texas |
United States | University of Iowa | Iowa City | Iowa |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | Morristown Medical Center | Morristown | New Jersey |
United States | Yale New Haven Hospital | New Haven | Connecticut |
United States | Columbia University Medical Center/NYPH | New York | New York |
United States | New York University | New York | New York |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Baylor Research Center | Plano | Texas |
United States | St. Francis Hospital | Roslyn | New York |
United States | Foundation for Cardiovascular Medicine | San Diego | California |
United States | Swedish Medical Center | Seattle | Washington |
United States | MedStar Washington Hospital Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Keystone Heart |
United States, Germany, Italy, Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Safety Endpoint - Composite Safety Endpoint Based on MACCE | Combined safety endpoint at 30 days defined according to VARC-2 ("TAVI early safety") as a composite of:
All-cause mortality - number of patients that expired All stroke (disabling and non-disabling) - defined by VARC-2 scale Life-threatening or disabled bleeding - BARC bleeding scale - 5 point scale ranging from no bleeding to fatal Acute kidney injury - Stage 2 or 3 (including renal replacement therapy) Coronary artery obstruction requiring intervention Major vascular complication, and Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR) - number of patients in whom a valve related dysfunction occurred It was pre-specified to combine all participants that received the device in the andomized Intervention and Roll-in Arms/Groups for this Outcome Measure. |
30 Days | |
Primary | Primary Efficacy Endpoint | Hierarchical composite efficacy endpt, determined by pair-wise comparisons among subjects according to hierarchy:
mortality or any stroke [30 days] death/stroke time to event analysis by days determine win stroke at same day the comparison moves to next tier NIHSS worsening [2-5 days post] Freedom from lesions detected by DW-MRI 2-5 days post Total volume lesions detected by DW-MRI 2-5 days post Each subj in intervention compared with each subj from control based on hierarchy according to Finkelstein-Schoenfeld method. If Subj A dies or has stroke &Subj B survives free of stroke to 30 days, Subj B wins(score+1) &Subj A loses (score-1). Both die or have stroke, patient with later event wins. Both have death/stroke on same day is equilibrium (score 0). Both are alive & have stroke on same day, comparison moves to next tier. Both stroke-free to 30 days, comparison moves to the next tier. Scores summed to cumulative score for each subj, &outcomes between groups are compared. |
Pre-discharge through 30-days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03003650 -
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis:CE-approval Cohort
|
N/A | |
Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
Active, not recruiting |
NCT04091048 -
Optimize PRO Study
|
||
Withdrawn |
NCT03247465 -
Image Fusion and Calcification Raising in Trans Aortic Valve Implantation
|
N/A | |
Completed |
NCT03143686 -
ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)
|
||
Active, not recruiting |
NCT05182307 -
DurAVR™ THV System: First-In-Human Study
|
N/A | |
Active, not recruiting |
NCT03466918 -
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
|
N/A | |
Completed |
NCT01819181 -
Women's INternational Transcatheter Aortic Valve Implantation Registry
|
||
Completed |
NCT04331145 -
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
|
Phase 4 | |
Recruiting |
NCT02803294 -
Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population
|
Phase 4 | |
Recruiting |
NCT04861805 -
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
|
N/A | |
Withdrawn |
NCT02088021 -
Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access
|
N/A | |
Terminated |
NCT02759237 -
The Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance (PMS) (CoreValve India PMS)
|
N/A | |
Recruiting |
NCT01794832 -
Severe Aortic Stenosis in Patients Referred for Valve Surgery
|
N/A | |
Completed |
NCT02424370 -
Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation
|
||
Completed |
NCT01493284 -
Portico TAVI Implant With Transfemoral Delivery System
|
N/A | |
Active, not recruiting |
NCT05712161 -
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
|
N/A | |
Completed |
NCT02664649 -
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
|
Phase 3 | |
Completed |
NCT01487330 -
First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System
|
N/A | |
Active, not recruiting |
NCT04722250 -
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
|
N/A |